Core Viewpoint - The article highlights five high-yield dividend stocks with yields ranging from 5.3% to 13.1%, which are positioned to provide significant income for investors in the upcoming year [1]. Group 1: Dividend Stocks Performance - Companies that consistently pay dividends tend to be profitable and provide a transparent long-term growth outlook, historically outperforming non-dividend stocks [2]. - A study by Hartford Funds and Ned Davis Research shows that dividend stocks have more than doubled the average annual return of non-payers (9.2% vs. 4.31%) over a 51-year period while being less volatile [3]. Group 2: Individual Stock Analysis - **Sirius XM Holdings**: Offers a yield of 5.27%, operates as a legal monopoly in satellite radio, and has a strong subscription-based revenue model [6][7][8]. The stock is valued at less than 7 times forward-year earnings, indicating a favorable investment opportunity [9]. - **Enterprise Products Partners**: Provides a yield of 6.78%, has increased its payout for 27 consecutive years, and operates a predictable cash flow model due to long-term fixed-fee contracts [10][11]. The stock is trading at less than 8 times forecast cash flow for 2026, presenting a value opportunity [13]. - **Realty Income**: Delivers a yield of 5.62%, pays dividends monthly, and has a strong track record of increasing payouts [15]. The company focuses on leasing to resilient businesses, and shares are valued at less than 13 times projected cash flow for 2026, offering a 19% discount to its historical average [16][18]. - **PennantPark Floating Rate Capital**: Features a yield of 13.09%, primarily invests in debt with a high weighted-average yield of 10.2% [20][21]. The company is trading at a 13% discount to its book value, indicating a potential value investment [23]. - **Pfizer**: Offers a yield of 6.83%, has seen a decline in share price, which has increased its dividend yield [25]. The company is expected to generate $62 billion in sales by 2025, with a strong oncology pipeline following its acquisition of Seagen [26][27]. Pfizer is valued at 8.4 times forward-year earnings, representing a 14% discount to its historical average [28].

These supercharged income stocks -- sporting an average yield of 8.51% -- can fatten investors' wallets in the new year.In 2025, Wall Street proved, yet again, why it's the premier wealth creator. The Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all rallied by double digits, with each index notching several record-closing highs.However, not all stocks are created equally. According to an analysis from Hartford Funds, buying and holding high-quality dividend stocks gives investors a high proba ...

Core Points - B. Riley Financial is facing significant challenges due to a scandal involving hedge fund investor Brian Kahn, who has been charged with criminal fraud [1][2] - Kahn's management buyout of Franchise Group, financed partly by $600 million in B. Riley debt, has been linked to substantial investor losses and the collapse of Prophecy Asset Management [2][4] - The Franchise Group filed for bankruptcy in November 2024, exacerbating B. Riley's financial troubles [6] Group 1 - Brian Kahn, who led a failed management buyout, has been charged with conspiracy to commit securities fraud, resulting in over $350 million in investor losses [2][4] - The criminal indictment against Kahn was linked to the collapse of Prophecy Asset Management, which had previously lost significant investor funds [3][4] - B. Riley Financial provided $600 million in debt for the management buyout and took a 31% stake in Franchise Group, which included brands like Vitamin Shoppe [5][6] Group 2 - The fallout from the hedge fund scandal and declining sales led to the bankruptcy of Franchise Group, impacting B. Riley's financial standing [6] - B. Riley has received SEC subpoenas regarding its dealings with Kahn and Franchise Group, indicating ongoing regulatory scrutiny [6]